Not losing weight on Ozempic? What the science says about GLP-1 non-response

What did @chanelica.r actually say?

The creator's core argument is straightforward: three weeks on semaglutide is too soon to judge whether it's working, because you're still on a starter dose that isn't yet therapeutic. She also recommends boosting protein and water intake, and suggests rotating injection sites weekly to potentially improve results and reduce side effects.

She's talking from personal experience, which she's upfront about. She's not citing studies, she's not playing doctor. But she does make a few claims that deserve scrutiny, particularly the injection site rotation one, which she herself calls "controversial." Credit where it's due: she's not overselling a magic fix. The main message is to be patient and set realistic expectations. That part is genuinely solid advice.

Does the science back this up?

Mostly, yes, on the timeline claims. The injection site claim is where things get murkier.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) enrolled participants on semaglutide 2.4 mg weekly, but the dose escalation period alone takes 16 to 20 weeks to reach that therapeutic level. Early-phase weight loss in the first four weeks is typically modest. A 2022 analysis of real-world semaglutide data published in Obesity found that meaningful weight loss, defined as 5 percent or more of body weight, generally didn't appear until week 8 to 12 at the earliest for most patients.

On protein: there is solid evidence that higher protein intake helps preserve lean mass during caloric restriction. Leidy et al. (2015, American Journal of Clinical Nutrition) showed that higher protein diets improve satiety and body composition outcomes, which matters when you're already experiencing some appetite suppression from GLP-1 therapy.

On injection sites and differential results: the clinical evidence here is thin. Pharmacokinetic studies (Kapitza et al., 2017, Journal of Clinical Pharmacology) show that subcutaneous absorption of semaglutide is relatively consistent across abdomen, thigh, and upper arm sites, with no clinically significant differences in drug exposure. The idea that different sites produce meaningfully different results is not well-supported in the literature.

What did they get wrong (or right)?

The timeline advice is right. The protein advice is right. The injection site claim is where the creator steps onto shakier ground.

She says "different injection sites can give different side effects and different results." The side effects part has some anecdotal backing, and a few small studies suggest nausea may vary slightly by site, but "different results" in terms of weight loss is not supported by pharmacokinetic data. Subcutaneous bioavailability of semaglutide is designed to be consistent regardless of injection location. Telling someone to rotate sites to see better weight loss outcomes is not evidence-based, even if rotation is generally recommended to avoid lipohypertrophy.

To be fair, the rotation recommendation itself is standard clinical practice, just not for the reason she's implying. You rotate sites to protect tissue integrity, not to boost efficacy. The advice isn't harmful, but the reasoning behind it is inaccurate.

She also gets credit for the "therapeutic dose" framing. That's a genuinely useful concept that many patients don't understand. Starting doses of semaglutide (0.25 mg weekly) are titration doses, not doses associated with significant weight loss in clinical trials.

What should you actually know?

If you're three weeks into semaglutide and frustrated, the creator's patience message is the right one. But here's a more complete picture.

• The maintenance dose in Wegovy trials is 2.4 mg weekly. Most people start at 0.25 mg. You are not at a therapeutic dose in week three, full stop.
• Weight loss on semaglutide is dose-dependent. The STEP trials showed a clear relationship between dose achieved and percent body weight lost.
• Protein intake does matter. GLP-1 drugs reduce overall caloric intake, and without adequate protein, a significant portion of weight lost can come from lean muscle mass, not fat. Aim for 1.2 to 1.6 grams per kilogram of body weight, per most clinical nutrition guidance.
• Rotating injection sites is good practice for tissue health, not for changing how the drug works. Don't rotate chasing better results. Rotate to protect your skin.
• If you're on a stable maintenance dose and still not losing weight after 12 to 16 weeks, that's a conversation for your prescriber, not a TikTok comment section.

Bottom line

This video is more responsible than most GLP-1 content on TikTok. The creator isn't selling anything, she's managing expectations, and she's giving broadly reasonable lifestyle advice. The injection site efficacy claim is the one place where personal experience has been presented as clinical fact when the data doesn't support it. That's worth knowing before you spend three weeks blaming your abdomen for your plateau.